Janus Henderson Group PLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 32,594 shares of the biotechnology company’s stock, valued at approximately $776,000.
A number of other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in Exelixis by 8.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,931,216 shares of the biotechnology company’s stock valued at $105,101,000 after acquiring an additional 480,986 shares in the last quarter. Vanguard Group Inc boosted its stake in Exelixis by 3.2% in the 3rd quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after purchasing an additional 834,478 shares during the period. Bank of Montreal Can boosted its stake in Exelixis by 4.0% in the 4th quarter. Bank of Montreal Can now owns 423,569 shares of the biotechnology company’s stock valued at $8,331,000 after purchasing an additional 16,369 shares during the period. James Investment Research Inc. boosted its stake in Exelixis by 875.3% in the 4th quarter. James Investment Research Inc. now owns 60,225 shares of the biotechnology company’s stock valued at $1,185,000 after purchasing an additional 54,050 shares during the period. Finally, IFP Advisors Inc boosted its stake in Exelixis by 188.2% in the 4th quarter. IFP Advisors Inc now owns 4,237 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 2,767 shares during the period. 78.27% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Patrick J. Haley sold 2,700 shares of Exelixis stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $23.47, for a total value of $63,369.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan M. Garber sold 30,000 shares of Exelixis stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $23.99, for a total value of $719,700.00. Following the sale, the director now directly owns 76,329 shares of the company’s stock, valued at approximately $1,831,132.71. The disclosure for this sale can be found here. In the last three months, insiders sold 555,930 shares of company stock valued at $12,363,512. Insiders own 4.50% of the company’s stock.
Several analysts recently issued reports on the company. ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research note on Friday, May 24th. BidaskClub upgraded Exelixis from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Morgan Stanley set a $27.00 target price on Exelixis and gave the company a “hold” rating in a research report on Thursday, May 2nd. Cowen reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research report on Tuesday, April 23rd. Finally, Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $26.00 target price for the company in a research report on Tuesday, April 16th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Exelixis has an average rating of “Buy” and an average target price of $28.88.
Shares of EXEL stock traded down $0.21 on Friday, hitting $19.70. 1,467,647 shares of the company’s stock were exchanged, compared to its average volume of 3,485,174. The company has a quick ratio of 7.48, a current ratio of 7.56 and a debt-to-equity ratio of 0.01. Exelixis, Inc. has a 12 month low of $13.42 and a 12 month high of $25.31. The company has a market cap of $6.01 billion, a P/E ratio of 13.78, a P/E/G ratio of 0.47 and a beta of 1.99.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share for the quarter, hitting the consensus estimate of $0.24. Exelixis had a return on equity of 37.21% and a net margin of 75.97%. The business had revenue of $215.49 million during the quarter, compared to the consensus estimate of $206.06 million. During the same period in the prior year, the company earned $0.40 EPS. Exelixis’s revenue for the quarter was up .8% on a year-over-year basis. As a group, equities research analysts anticipate that Exelixis, Inc. will post 0.92 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Janus Henderson Group PLC Acquires New Position in Exelixis, Inc. (NASDAQ:EXEL)” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://sundanceherald.com/2019/06/14/janus-henderson-group-plc-purchases-shares-of-32594-exelixis-inc-exel.html.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.